Cerebrolysin is the most widely used neuropeptide preparation globally, approved in over 50 countries for neurological conditions. As a complex mixture of brain-derived peptides, it provides multi-target neurotrophic support rather than acting through a single receptor pathway.
Research Applications
Approved clinical indications (non-US) include post-stroke recovery, vascular and Alzheimer’s dementia, traumatic brain injury, and pediatric neurodevelopmental support. Research contexts include neuroplasticity, neuroprotection, and cognitive rehabilitation.
Dosage Information (Research Use)
Clinical protocols: 10-30 mL IV infusion or IM injection daily for 10-20 day courses. Repeated courses at intervals. Requires medical supervision.
Reconstitution & Handling
Supplied as ready-to-use solution. Dilute in 0.9% saline for IV infusion. Do not mix with other medications.
Half-Life & Pharmacokinetics
Complex mixture — individual peptide components have varying half-lives. Functional neuroprotective effects persist beyond plasma clearance.
Reported Observations in Literature
Generally well-tolerated in clinical use. Headache, dizziness, injection site reactions. Rare: agitation, confusion (typically in elderly patients at higher doses).
Key Research References
- Chen N, et al. “Cerebrolysin for vascular dementia.” Cochrane Database Syst Rev. 2013
- Muresanu DF, et al. “Cerebrolysin and Recovery After Stroke (CARS).” J Neural Transm. 2016